Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
DMD Systems Recovery, LLC (DMD), a Reuse First® IT Asset Disposition (ITAD) provider and Certified B Corporation, has earned ...
After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...
Pharmaceutical Technology on MSN
Santhera grants Agamree rights to Nxera for DMD
In October 2025, Health Canada approved Agamree from Santhera for the treatment of DMD in individuals aged four years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback